NOVEL VACCINE COMPOSITION
An inactivated influenza virus preparation is described which comprises a haemagglutinin antigen stabilised in the absence of thiomersal, or at low levels of thiomersal, wherein the haemagglutinin is detectable by a SRD assay. The influenza virus preparation may comprise a micelle modifying excipient, for example α-tocopherol or a derivative thereof in a sufficient amount to stabilise the haemagglutinin.
1 . A method for raising an immune response in a human subject, comprising a step of administering to the human subject a mercurial preservative-free immunogenic composition comprising an aqueous inactivated influenza virus preparation comprising a haemagglutinin (HA) and at least one of α-tocopherol or a derivative thereof in an amount sufficient to stabilize said HA.
2 . The method of claim 1 , wherein the human subject is a child.
3 . The method of claim 1 , wherein the at least one of α-tocopherol or a derivative thereof is present in an amount such that the HA of said preparation remains stable for at least 6 months after said preparation is produced as determined by the presence of an amount of HA detectable by SRD assay.
4 . The method of claim 1 , wherein said preparation comprises α-tocopherol.
5 . The method of claim 1 , wherein said preparation comprises α-tocopherol succinate.
6 . The method of claim 5 , wherein the α-tocopherol succinate is present at a concentration between 1 ug/ml and 10 mg/ml.
7 . The method of claim 5 , wherein the α-tocopherol succinate is present at a concentration between 10 and 500 ug/ml.
8 . The method of claim 1 , wherein the influenza virus antigen preparation is selected from the group of: split virus antigen preparations, subunit antigens, and chemically or otherwise inactivated whole virus.
9 . The method of claim 8 , wherein the inactivated influenza virus preparation is a split or sub-unit virus antigen preparation.
10 . The method of claim 1 , wherein the inactivated influenza virus preparation comprises both A and B strain HA.
11 . The method of claim 10 , wherein the preparation is a trivalent influenza virus preparation comprising 2 A strains and 1 B strain HA.
12 . The method of claim 10 , wherein the preparation is a tetravalent influenza virus preparation comprising 2 A strains and 2 B strains HA.
13 . The method of claim 10 , wherein the concentration of HA antigen for each strain of influenza is 1-100 μg per ml, as measured by a SRD assay.
14 . The method of claim 10 , wherein the concentration of HA antigen for each strain of influenza is about 15 μg per ml, as measured by a SRD assay.
15 . The method of claim 10 , wherein the concentration of HA antigen for each strain of influenza is less than 15 μg per ml, as measured by a SRD assay.
16 . The method of claim 15 , wherein the amount of HA antigen for each strain of influenza is between 6-9 μg per dose, as measured by a SRD assay.
17 . The method of claim 1 , wherein the immunogenic composition additionally comprises an adjuvant.
18 . The method of claim 17 , wherein the adjuvant comprises an oil-in-water emulsion.
19 . The method of claim 18 , wherein the adjuvant comprises squalene.
20 . The method of claim 17 , wherein the adjuvant comprises a tocol such as tocopherol.
21 . A method of claim 1 , wherein the child is below 9 years or below 6 years of age.
22 . A method of claim 21 , wherein the child is between 6 months and <6 years of age.
23 . A method of claim 21 , wherein the child is between 6 months and <36 months of age.
24 . The method of claim 21 , wherein the child is between 36 months and <6 years of age.
25 . The method of claim 1 , wherein the immunogenic composition has a dose volume of about 0.5 ml or of about 0.25 ml.
26 . The method of claim 1 , wherein the immunogenic composition has a dose volume of between 0.2 to 0.45 ml.
27 . A method of claim 1 , in which the delivery of the immunogenic composition is via the intradermal, intranasal, intramuscular, oral or subcutaneous route.
28 . A mercurial preservative-free pediatric vaccine comprising an aqueous inactivated influenza virus preparation comprising a haemagglutinin (HA) and at least one of α-tocopherol or a derivative thereof in an amount sufficient to stabilize said HA, wherein the dose volume is between 0.2 to 0.45 ml.